| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, College of Physicians and Surgeons (Drs. Kaufmann, Gordon, Rowland, and Mitsumoto, and M.L. DelBene and V. Battista), and the Department of Biostatistics, Mailman School of Public Health (Drs. Levy, Thompson, and Levin), Columbia University, New York, NY.
Address correspondence and reprint requests to Dr. Petra Kaufmann, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032; e-mail: pk88{at}columbia.edu
Objective: To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale–revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in an ALS clinic population.
Methods: The authors prospectively evaluated 267 consecutive patients with ALS at first visit to an ALS clinic using the ALSFRSr and pulmonary function testing. The association of ALSFRSr score at baseline with death or tracheostomy in ALS was examined using Cox proportional hazards models, adjusting for age at baseline, sex, and symptom duration.
Results: Of 267 patients with ALS, 103 (39%) reached the endpoint, defined as either death (79 patients) or tracheostomy (24 patients), during a mean follow-up of 1.0 ± 0.7 years. Among the 103 patients who reached the endpoint during follow-up, 77 (75%) had a baseline ALSFRSr score of less than 38 (the median baseline score of all patients), compared to 53 of 164 (32%) who remained alive without tracheostomy. Patients with a total ALSFRSr score below the median had a 4.4-fold increased risk of death or tracheostomy compared to those who scored above the median (HR: 4.38, 95% CI: 2.79 to 6.86, p < 0.001). Both the total ALSFRSr score at baseline (HR: 0.94, 95% CI: 0.91 to 0.98, p < 0.001) and forced vital capacity at baseline (HR: 0.99, 95% CI: 0.98 to 1.00, p = 0.02) were associated with death or tracheostomy when included in the same Cox model.
Conclusions: In an ALS clinic population, the total Amyotrophic Lateral Sclerosis Functional Rating Scale–revised score at baseline is a strong predictor of death or tracheostomy independently of forced vital capacity and after adjustment for age at baseline, sex, and symptom duration.
Received February 10, 2004. Accepted in final form September 15, 2004.
This article has been cited by other articles:
|
|
 |
|
  D. Lo Coco, S. Marchese, V. La Bella, T. Piccoli, and A. Lo Coco The Amyotrophic Lateral Sclerosis Functional Rating Scale Predicts Survival Time in Amyotrophic Lateral Sclerosis Patients on Invasive Mechanical Ventilation Chest, July 1, 2007; 132(1): 64 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mitsumoto, A. M. Ulug, S. L. Pullman, C. L. Gooch, S. Chan, M. -X. Tang, X. Mao, A. P. Hays, A. G. Floyd, V. Battista, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS Neurology, April 24, 2007; 68(17): 1402 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S Baek and N. P Desai ALS: pitfalls in the diagnosis Practical Neurology, April 1, 2007; 7(2): 74 - 81. [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Cheung, P. H. Gordon, and B. Levin Selecting promising ALS therapies in clinical trials Neurology, November 28, 2006; 67(10): 1748 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Czaplinski, L. J. Haverkamp, A. A. Yen, E. P. Simpson, E. C. Lai, and S. H. Appel The value of database controls in pilot or futility studies in ALS Neurology, November 28, 2006; 67(10): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Kalra, A Vitale, N R Cashman, A Genge, and D L Arnold Cerebral degeneration predicts survival in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1253 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Montes, G. Levy, S. Albert, P. Kaufmann, R. Buchsbaum, P. H. Gordon, and H. Mitsumoto Development and evaluation of a self-administered version of the ALSFRS-R. Neurology, October 10, 2006; 67(7): 1294 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Gordon, Y. K. Cheung, and F. Kimura Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology, October 10, 2006; 67(7): 1314 - 1315. [Full Text] [PDF]
|
|
|
|
|
|
B. Levin, T. G, L. H. Mitsumoto, P. Kaufmann, V . Meininger, B . Asselain, P .N. Leigh, A . Ludolph, L . Lacomblez, and P . Guillet Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial Neurology, June 13, 2006; 66(11): 1786 - 1787. [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Carvalho and M. Swash Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol, April 1, 2006; 63(4): 557 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Levy, P. Kaufmann, R. Buchsbaum, J. Montes, A. Barsdorf, R. Arbing, V. Battista, X. Zhou, H. Mitsumoto, B. Levin, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS Neurology, March 14, 2006; 66(5): 660 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Czaplinski, A A Yen, and S H Appel Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 390 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kimura, C. Fujimura, S. Ishida, H. Nakajima, D. Furutama, H. Uehara, K. Shinoda, M. Sugino, and T. Hanafusa Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS Neurology, January 24, 2006; 66(2): 265 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Meininger, B. Asselain, P. Guillet, P. N. Leigh, A. Ludolph, L. Lacomblez, W. Robberecht, and for the Pentoxifylline European Group Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial Neurology, January 10, 2006; 66(1): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
